Safety and Pharmacokinetics of Single and Multiple Ascending Doses of 3K3A-APC in Healthy Adult Volunteers

Overview

The purpose of this study is to evaluate the safety and pharmacokinetic profile of single and multiple ascending intravenous doses of 3K3A-APC in healthy adult subjects aged 18-55 years.

Full Title of Study: “A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of 3K3A-APC, a Recombinant Variant of Human Activated Protein C (APC), in Healthy Adult Volunteers”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Other
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: December 2012

Detailed Description

This is a single-center, sequential-cohort, double-blind, placebo-controlled, single- and multiple-ascending dose study. Eligible adult subjects will be assigned sequentially to 1 of 10 cohorts, at successively higher single doses, followed by successively higher multiple doses. Single IV Doses: 5 subjects per cohort, aged 18-55, will be randomized in a 4:1 manner to receive active drug (6, 30, 90, 180, 360, and TBD µg/kg) or to receive matching placebo (Cohorts 1-6). Multiple IV Doses: 8 subjects per cohort, aged 18-55, will be randomized in a 3:1 manner to receive active drug (90, 180, 360, and TBD µg/kg) or to receive matching placebo every 12 hours for 5 doses (Cohorts 7-10). Single-Dose Cohorts Subjects receiving a single dose will be confined in a Phase 1 unit for 12 hours prior to dosing, during dosing, and for 24 hours after dosing (Study Day 1-2) for observation and PK sampling. Subjects will return on Study Day 4 (~72 hours after infusion) and Study Day 15 for additional safety evaluations. A 28-Day follow-up phone call will be made to subjects to collect AEs that occur within 28-days of the dose. Multiple-Dose Cohorts Subjects receiving multiple doses will be confined in a Phase 1 unit for 12 hours prior to dosing through 24 hours following the last dose (Study Day 1-4) for observation and PK sampling. Subjects will return on Study Day 6 (~72 hours after last infusion) and Study Day 15 for additional safety evaluations. A 28-Day follow-up phone call will be made to subjects to collect AEs that occur within 28-days of the last dose.

Interventions

  • Biological: 3K3A-APC, diluted in 0.9% sodium chloride in water
  • Drug: 0.9% NaCl in water

Arms, Groups and Cohorts

  • Active Comparator: 6 µg/kg 3K3A-APC, single-dose
    • Cohort 1: 6 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 20 mL IV infusion over 15 minutes
  • Active Comparator: 30 µg/kg 3K3A-APC, single-dose
    • Cohort 2: 30 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
  • Active Comparator: 90 µg/kg 3K3A-APC, single-dose
    • Cohort 3: 90 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
  • Active Comparator: 180 µg/kg 3K3A-APC, single-dose
    • Cohort 4: 180 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
  • Active Comparator: 360 µg/kg 3K3A-APC, single-dose
    • Cohort 5: 360 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
  • Active Comparator: TBD µg/kg 3K3A-APC, single-dose
    • Cohort 6: TBD (not to exceed 720) µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
  • Active Comparator: 90 µg/kg 3K3A-APC, q12h for 5 doses
    • Cohort 7: 90 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
  • Active Comparator: 180 µg/kg 3K3A-APC, q12h for 5 doses
    • Cohort 8: 180 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
  • Active Comparator: 360 µg/kg 3K3A-APC, q12h for 5 doses
    • Cohort 9: 360 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
  • Active Comparator: TBD µg/kg 3K3A-APC, q12h for 5 doses
    • Cohort 10: TBD (not to exceed 720) µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
  • Placebo Comparator: Matching Placebo, 0.9% NaCl in water
    • Cohorts 1-10: 0.9% sodium chloride in water and administered as either 20 mL IV infusion over 15 minutes (Cohort 1), or 100 mL IV infusion over 15 minutes (Cohorts 2-10)

Clinical Trial Outcome Measures

Primary Measures

  • Adverse Events That Meet Dose-limiting Toxicity Criteria Specified in Protocol.
    • Time Frame: Day 4 for single-dose cohorts
  • Adverse Events That Meet Dose-limiting Toxicity Criteria Specified in the Protocol.
    • Time Frame: Day 6 for multiple-dose cohorts

Secondary Measures

  • Maximum Observed Plasma Concentration (Cmax) of 3K3A-APC by Non-compartmental Analysis
    • Time Frame: 0, 5, 10, 15, 20, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose
    • Single-dose cohorts
  • Time at Which Cmax is Observed (Tmax) for 3K3A-APC by Non-compartmental Analysis
    • Time Frame: 0, 5, 10, 15, 20, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose
    • Single-dose cohorts
  • Area Under the Plasma Concentration-time Curve From Time 0 to the Final Time With a Concentration ≥ Limit of Quantitation [AUC(0-t)] for 3K3A-APC by Non-compartmental Analysis
    • Time Frame: 0, 5, 10, 15, 20, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose
    • Single-dose cohorts
  • Area Under the Plasma Concentration-time Curve From Time 0 to Infinity [AUC(0-inf)] for 3K3A-APC by Non-compartmental Analysis
    • Time Frame: 0, 5, 10, 15, 20, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose
    • Single-dose cohorts
  • Elimination Rate Constant (λz) for 3K3A-APC by Non-compartmental Analysis
    • Time Frame: 0, 5, 10, 15, 20, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose
    • Single-dose cohorts
  • Half-life (t1/2) of 3K3A-APC by Non-compartmental Analysis
    • Time Frame: 0, 5, 10, 15, 20, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose
    • Single-dose cohorts
  • Total Clearance (CL) of 3K3A-APC by Non-compartmental Analysis
    • Time Frame: 0, 5, 10, 15, 20, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose
    • Single-dose cohorts
  • Volume of Distribution (Vz) of 3K3A-APC by Non-compartmental Analysis
    • Time Frame: 0, 5, 10, 15, 20, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose
    • Single-dose cohorts
  • Maximum Observed Plasma Concentration (Cmax) of 3K3A-APC by Compartmental Analysis
    • Time Frame: 0, 5, 10, 15, 20, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose
    • Single-dose cohorts
  • Area Under the Plasma Concentration-time Curve From Time 0 to Infinity [AUC(0-inf)] for 3K3A-APC by Compartmental Analysis
    • Time Frame: 0, 5, 10, 15, 20, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose
    • Single-dose cohorts; primary parameters (CL, V) were used to fit the model. Secondary parameters (Cmax, AUC(inf), λz, t1/2) were estimated from the primary parameters.
  • Elimination Rate Constant (λz) for 3K3A-APC by Compartmental Analysis
    • Time Frame: 0, 5, 10, 15, 20, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose
    • Single-dose cohorts; primary parameters (CL, V) were used to fit the model. Secondary parameters (Cmax, AUC(inf), λz, t1/2) were estimated from the primary parameters.
  • Half-life (t1/2) of 3K3A-APC by Compartmental Analysis
    • Time Frame: 0, 5, 10, 15, 20, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose
    • Single-dose cohorts; primary parameters (CL, V) were used to fit the model. Secondary parameters (Cmax, AUC(inf), λz, t1/2) were estimated from the primary parameters.
  • Total Clearance (CL) of 3K3A-APC by Compartmental Analysis
    • Time Frame: 0, 5, 10, 15, 20, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose
    • Single-dose cohorts; primary parameters (CL, V) were used to fit the model. Secondary parameters (Cmax, AUC(inf), λz, t1/2) were estimated from the primary parameters.
  • Volume of Distribution (V) of 3K3A-APC by Compartmental Analysis
    • Time Frame: 0, 5, 10, 15, 20, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 6 and 8 hours post-dose
    • Single-dose cohorts; primary parameters (CL, V) were used to fit the model. Secondary parameters (Cmax, AUC(inf), λz, t1/2) were estimated from the primary parameters.
  • Maximum Observed Plasma Concentration (Cmax) of 3K3A-APC by Compartmental Analysis
    • Time Frame: 0, 20 minutes and 1 hour post for doses 1 and 5
    • Multiple-dose cohorts; primary parameters (CL, V) were used to fit the model. Secondary parameters (Cmax, AUC(inf), λz, t1/2) were estimated from the primary parameters.
  • Area Under the Plasma Concentration-time Curve From Time 0 to Infinity [AUC(0-inf)] for 3K3A-APC by Compartmental Analysis
    • Time Frame: 0, 20 minutes and 1 hour post for doses 1 and 5
    • Multiple-dose cohorts; primary parameters (CL, V) were used to fit the model. Secondary parameters (Cmax, AUC(inf), λz, t1/2) were estimated from the primary parameters.
  • Elimination Rate Constant (λz) for 3K3A-APC by Compartmental Analysis
    • Time Frame: 0, 20 minutes and 1 hour post for doses 1 and 5
    • Multiple-dose cohorts; primary parameters (CL, V) were used to fit the model. Secondary parameters (Cmax, AUC(inf), λz, t1/2) were estimated from the primary parameters.
  • Half-life (t1/2) of 3K3A-APC by Compartmental Analysis
    • Time Frame: 0, 20 minutes and 1 hour post for doses 1 and 5
    • Multiple-dose cohorts; primary parameters (CL, V) were used to fit the model. Secondary parameters (Cmax, AUC(inf), λz, t1/2) were estimated from the primary parameters.
  • Total Clearance (CL) of 3K3A-APC by Compartmental Analysis
    • Time Frame: 0, 20 minutes and 1 hour post for doses 1 and 5
    • Multiple-dose cohorts; primary parameters (CL, V) were used to fit the model. Secondary parameters (Cmax, AUC(inf), λz, t1/2) were estimated from the primary parameters.
  • Volume of Distribution (V) of 3K3A-APC by Compartmental Analysis
    • Time Frame: 0, 20 minutes and 1 hour post for doses 1 and 5
    • Multiple-dose cohorts; primary parameters (CL, V) were used to fit the model. Secondary parameters (Cmax, AUC(inf), λz, t1/2) were estimated from the primary parameters.

Participating in This Clinical Trial

Inclusion Criteria

1. Healthy males or non-pregnant, non-lactating females 2. Both men and women of child-bearing potential (i.e., not surgically sterile or post-menopausal defined as age > 40 years without menses for ≥ 2 years) must agree to use a barrier method of contraception plus a spermicide throughout the study. 3. Age 18 to 55 years, inclusive 4. Body Mass Index (BMI) of 19 to 30 kg/m2, inclusive (see APPENDIX B) 5. Willing and able to complete all study visits 6. Agreement to abstain from smoking and drinking alcoholic beverages from 48 hours prior to randomization through last Study Day (15) 7. Signed informed consent form (ICF) Exclusion Criteria:

1. Any medical problem for which the subject is being evaluated and/or treated 2. Activated partial thromboplastin time (aPTT) greater than upper limit of normal (ULN) 3. Platelet count < 125,000 cells/mm3 4. International Normalized Ratio (INR) > 1.3 5. Any other clinically significant abnormalities in laboratory values (chemistries, hematology, coagulation studies, and urinalysis – see APPENDIX C) 6. Clinically significant abnormalities on electrocardiogram (ECG) 7. Positive serum βHCG pregnancy test at screening or on Study Day -1 (for all women, regardless of child-bearing potential) 8. Positive urine drug screen at screening or on Study Day -1 (see APPENDIX C) 9. Positive blood test for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody 10. Known family history of bleeding or blood clotting disorders 11. History of bleeding diathesis 12. History of liver disease with ongoing coagulopathy 13. Use of any prescription or non-prescription medications or supplements within 7 days prior to Study Day -1, excluding hormonal contraceptives 14. Use of anticoagulant medication within 14 days prior to Study Day -1 15. Major surgery within 60 days prior to Study Day -1 16. Receipt of an investigational drug within 30 days prior to Study Day -1 17. Donation of blood or plasma within 30 days prior to Study Day -1 18. Any other condition, that in the opinion of the Site Investigator, may adversely affect the safety of the subject, the subject's ability to complete the study, or the outcome of the study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • ZZ Biotech, LLC
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Patrick D Lyden, MD, FAAN, Principal Investigator, Cedars-Sinai Medical Center
    • Howard Levy, MD, PhD, MMM, Study Director, ZZ Biotech, LLC

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.